Drug Topics
MAY 2, 2024
The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).
STAT
MAY 2, 2024
When male Sumatran orangutans let out a long call, they’re usually trying to grab female attention. But the sounds — a booming blend of roars and grunts — can end up attracting unwanted attention from other males, too. Things can get tense. Which is likely how Rakus, an adult male orangutan frequently seen in Gunung Leuser National Park in South Aceh, Indonesia, acquired a face wound in June 2022.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MAY 2, 2024
A review found that many guidelines that recommended pharmacogenetic testing were inconsistent between clinical associations.
STAT
MAY 2, 2024
As agricultural authorities and epidemiologists try to get their arms around the scope of the latest confounding chapter in the decades-long story of the H5N1 avian influenza virus — its j ump into U.S. herds of dairy cattle — they’re turning to the genetic breadcrumbs the virus leaves behind in the animals’ nose, lungs, and, primarily, milk.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
MAY 2, 2024
Currently, the treatment is being evaluated in the phase 3 CALYPSO study to further prove the safety and efficacy in patients with hypoparathyroidism.
STAT
MAY 2, 2024
Another upload of genetic sequence data from the H5N1 bird flu outbreak in dairy cattle has exacerbated the scientific community’s frustration with the U.S. Department of Agriculture after the agency again failed to include basic information needed to track how the virus is changing as it spreads. Like a large tranche of sequences that the USDA uploaded to a public database on April 21, this week’s data dump did not include information about where and when the sequenced samples wer
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
MAY 2, 2024
Google and DeepMind released an open access paper on their newest artificial intelligence tools intended for use in hea | Results released by Google on Med-Gemini's performance show that it outperforms existing AI/ML including GPT-4 on over a dozen industry benchmarks.
STAT
MAY 2, 2024
It’s no secret that a lucky few seem to glide into old age, the years settling gracefully on their bodies, while others appear to have been dragged through time tied to a metaphorical garbage truck. Biologists have been developing numerous ways to measure the rate an individual ages — often called an accelerated or decelerated “biological age” — and trying to translate it into a heightened or reduced risk of the morbidity and mortality that comes with aging.
Pharmacy Times
MAY 2, 2024
The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.
STAT
MAY 2, 2024
If, after reading the latest recommendation on breast cancer screening by the United States Preventive Services Task Force (USPSTF), you feel like your head is spinning, that’s understandable. The task force’s newest advice , which gives a “B” grade in favor of routine mammograms for women in their 40s, reverses its 2016 statement saying the test should be optional for such women.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
MAY 2, 2024
Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.
STAT
MAY 2, 2024
Families in America should never have to scrounge for baby formula. The United States needs a diverse and resilient supply of infant formula. Boosting the ability of smaller companies to compete in this market against the three large formula makers — Abbott, Mead Johnson, and Nestlé Gerber — could help make shortages a thing of the past.
Pharmacy Times
MAY 2, 2024
This class of drugs, including semaglutide, liraglutide, and tirzepatide, is used to treat type 2 diabetes and obesity.
Fierce Healthcare
MAY 2, 2024
Retail pharmacy giant Walgreens inked another partnership to recruit participants for research as it continues to build out its clinical trials business. | Walgreens has signed more than 35 clinical trial contracts with drugmakers including Freenome and Prothena. The aim is to optimize recruitment and make clinical trials more accessible, inclusive and equitable, the companies said.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
MAY 2, 2024
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer treatments with a new acquisition. Novartis is paying $1 billion upfront and up to an additional $750 million if certain milestones are met to acquire startup Mariana Oncology, the latter company announced Thursday.
Pharmaceutical Technology
MAY 2, 2024
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
STAT
MAY 2, 2024
In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious legal theory that thousands of HIV patients have used in a closely watched case to argue drugmakers can be held negligent for failing to develop a medicine. Earlier this year, a state appeals court ruled the company could be held liable for halting further development of an HIV medicine that was safer than an HIV drug it was already selling.
Fierce Pharma
MAY 2, 2024
Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug. | Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics for the Danish company's popular GLP-1 drug.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
MAY 2, 2024
Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s podcast with Zach Powers, chief information security officer at Benchling, the R&D cloud platform for the biotech industry.
Pharmacy Times
MAY 2, 2024
Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies
STAT
MAY 2, 2024
Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman, today announced $126 million in Series D funding valuing the company at $2.2 billion. The investment round was led by venture capital giant General Catalyst and 7wireVentures, where Tullman is a managing partner. Transcarent will use the funding to support development of artificial intelligence capabilities across the enterprise, growing its business, and pursuing acquisitions, Tullman told S
Drug Topics
MAY 2, 2024
Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.
Fierce Healthcare
MAY 2, 2024
The Cigna Group posted a $277 million loss in Q1 on the back of investment losses, according to its earnings report released Thursday. | The Cigna Group posted a $277 million loss in Q1 on the back of investment losses, according to its earnings report released Thursday.
STAT
MAY 2, 2024
Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company charges. Speaking on an earnings call Thursday, CEO Lars Fruergaard Jørgensen said the company launched the treatments at similar prices to earlier generations in the drug class, despite their having greater efficacy, making them “an attractive value proposition.
European Pharmaceutical Review
MAY 2, 2024
Interim results of an ongoing study published in The Lancet have reported that Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalisations by 82 percent in infants under six months, compared to infants who received no RSV intervention. Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.
STAT
MAY 2, 2024
Amgen said Thursday that it will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate that’s seen as a potential competitor to Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The injectable drug, called MariTide, is in a Phase 2 trial for obesity, and Chief Executive Bob Bradway said on an earnings call that “we are very encouraged with the results” from an interim analysis of that trial.
Fierce Healthcare
MAY 2, 2024
Hospitals’ margins and revenues took a slight dip in March, though it wasn’t enough to sour what has been a strong quarter for the sector. | Revenues, volumes and margins pulled back from February to March, with the strongest decline seen among outpatient settings. Sectorwide reports and recent earnings suggest that the sector is still well ahead of 2023.
pharmaphorum
MAY 2, 2024
Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries.
Fierce Pharma
MAY 2, 2024
As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a unique win in previously untreated mantle cell lymphoma (MCL). | AstraZeneca is touting a earlier-than-expected positive readout for Calquence in first-line mantle cell lymphoma. But a big question remains whether it can immediately file with the FDA, especially given the precedent of Imbruvica.
pharmaphorum
MAY 2, 2024
A personalised vaccine for the aggressive brain cancer glioblastoma developed has shown encouraging signs of efficacy in its first human trial.
European Pharmaceutical Review
MAY 2, 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023. Following publication of this white paper, the government requested that the MHRA outline the steps the agency is working on in relation to its expectations.
pharmaphorum
MAY 2, 2024
The updated ICH E6(R3) Good Clinical Practice guidelines are here - discover what's changed and how clinical trials will need to adapt. This in-depth post unravels the key impacts of E6(R3).
STAT
MAY 2, 2024
WASHINGTON — Members of Congress appear poised to advance another short-term extension of pandemic-era telehealth flexibilities instead of permanently addressing the issue, seven sources familiar with the talks said. During the Covid-19 pandemic, lawmakers allowed Medicare patients to access telehealth services in more places and for a greater variety of providers than before, but some of those flexibilities are set to expire at the end of the year.
Expert insights. Personalized for you.
220 
Let's personalize your content